A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was what is the optimal target INR for warfarin therapy in patients who have undergone implantation of a prosthetic mechanical mitral heart valves? Altogether 894 papers were identified on Medline and 1235 on Embase using the reported search including all major international guidelines. Twelve papers and publications represented the best evidence on the topic. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses were tabulated. We conclude that after implantation of new generation prosthetic mechanical mitral valves, patients should receive warfarin to a target INR of 2.5-3.5. For older types of valve the target INR should be 3.5-4.5. Warfarin therapy should be administered to maintain stable INR values ensuring lowest possible variation in the intensity of anticoagulation. In selected patients with a history of thromboembolic disease andyor coronary artery disease warfarin therapy consideration should be given to supplementing warfarin with low-dose aspirin.
Introduction
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in the ICVTS w1x.
Clinical scenario
You have inserted a mechanical prosthetic mitral heart valve into a 60-year-old man. He subsequently has a GI bleed while on warfarin so you decide to review the literature to confirm optimal therapeutic INR which minimises long-term thromboembolic and haemorrhagic complications.
Three-part question
In patients with wmechanical prosthetic mitral valvex receiving long-term wwarfarin therapyx what is the woptimal therapeutic INR targetx? 
Search strategy

Search outcome
A total of 894 papers on Medline and 1235 on Embase were found using the above search. All major guidelines were included, and their reference lists searched. Twelve Downloaded from https://academic.oup.com/icvts/article-abstract/6/3/390/667825 by guest on 23 January 2019 papers were considered to represent the best evidence on the topic and are summarised in Table 1 .
Results
The thrombogenic characteristics of prosthetic mechanical heart valves are well recognised w14, 15x necessitating postoperative anticoagulation therapy. However, it is important to achieve an anticoagulation balance which prevents both adverse thromboembolic events w16, 17x and bleeding w18x. There can also be variability of warfarin effects which when outwith a predetermined 'target' INR range is associated with higher risks of valve related thromDownloaded from https://academic.oup.com/icvts/article-abstract/6/3/390/667825 by guest on 23 January 2019 boembolic or haemorrhagic mortality w16, 17x. Finally, prosthetic valves themselves vary in their thrombogenic properties w12, 19, 20x.
Several major guidelines have been published which attempt to identify an 'optimal' target INR for patients with mechanical mitral valves. However, with a scarcity of large randomised trials, most guidelines are based on cohort studies and case series, a fact acknowledged by the groups themselves. The sixth and seventh ACCP guidelines recommend a target INR of 2.5-3.5 in patients with tilting disc and bi-leaflet mechanical valves in the mitral position w2, 3x. For older generation valves (caged ball or disc) or in patients with additional risk factors, the addition of low dose aspirin 75-100 mgyday is recommended. Previous concerns about increased bleeding events in patients receiving both aspirin and vitamin-K antagonists are somewhat allayed by studies demonstrating significant decreases in thromboembolic events with combination therapy without significant differences in bleeding events w21x. Comparable results have been reported in other studies w22x. However, as emphasised in these guidelines the benefits of antiplatelet therapy combined with warfarin needs to be evaluated on the basis of total daily aspirin dose and variability of INR within and between groups of patients.
Dose-dependent bleeding risk with aspirin combined with warfarin is also reported in the 1998 AHAyACC guidelines which were revised in 2006 w4, 5x. In parallel with the ACCP guidelines these recommend an INR target of 2.5-3.5 for newer generation mechanical mitral valves. A target of 3.0-4.5 should be considered in patients with valves of increased thrombogenicity. However, whilst the 1998 guideline suggests supplementation with aspirin in those patients with additional thromboembolic risk factors w4x, by 2006 it has become a Class I Level B recommendation with Clopidogrel being advised for those unable to take Aspirin w5x.
The most recent European guidelines have come from the European Society of Cardiologists (ESC) w6x, the British Committee for Standards in Haematology (BCSH) w7x and The Scottish Intercollegiate Guidelines Network (SIGN) w8x. In common with the American guidelines, these support a target INR of 2.5-3.5 for second generation prosthetic mechanical mitral valves. However, the European and UK based guidelines are more restrained regarding supplementary aspirin with the BCSH making no comment and the ESC and SIGN advocating a cautious approach to addition of an antiplatelet agent, recommending use in high-risk cases only after thorough risk factor identification and warfarin optimisation. However, despite these slight differences between USA and European guidelines no studies have examined whether these produce clinically different outcomes.
As acknowledged by all guidelines there are few good RCTs or cohort studies available. This may in part reflect ethical considerations at a time when expert committees are producing contemporary evidence-based guidelines. In 1991, Butchart et al. published a cohort study comparing mean target INRs of 2.5 and 3.0 in patients who had received a Medtronic-Hall mitral prosthesis w9x. Embolic and haemorrhagic event-free survival was greater with a higher INR and they concluded that an INR above 3 was appropriate. However, there were possible confounding factors with this study, not least that patients with lower INRs had surgery 5-10 years earlier than those with higher INRs.
In 1995 Cannegieter et al. studied adverse haemorrhagic or thromboembolic events in patients who had undergone valve replacement reporting an optimal INR range of 2.5-4.9 w10x. A literature review by Tiede et al. in 1998 recommended an INR of 3.3-3.7 for tilting disc and 2.8-3.2 for other valves w11x. A more recent meta-analysis including nearly 10,000 patients from 30 studies concluded that an INR over 3.0 was associated with lower risks of thromboembolic complications without increased bleeding risk w12x. However, their study patients were relatively young and excluded if on anti-platelet therapy, and they did not provide data on either the achieved INR levels or INR variability. Unfortunately these three studies included all types of valve and valve position with little if any subgroup analysis. Finally, an RCT by Pengo et al. found no significant difference in systemic thromboembolism and vascular death between patients with target INRs three and four, although 'major' and 'minor' haemorrhage were significantly greater in the higher INR group w13x. Once again this study included all valve types with no subgroup analysis.
Clinical bottom line
In patients with newer generation mechanical prosthetic mitral valves the INR should be maintained at 2.5-3.5. For older type valves the INR should be 3.5-4.5. Some patients with no contraindications to anti-platelet therapy at increased risk of thromboembolic episodes may benefit from additional low-dose aspirin therapy (75-100 mgyd). To decrease the risk of thromboembolic and haemorrhagic events associated with anticoagulation therapy it is imperative to ensure a low variability in the level of anticoagulation.
